Indication
Parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.
Medicine details
- Medicine name:
- palopegteriparatide (Yorvipath)
- SMC ID:
- SMC3007
- Pharmaceutical company
- Ascendis Pharma
- BNF chapter
- Endocrine system
- Submission type
- Resubmission
- Publication due date:
- 08 February 2027
- SMC meeting date:
- 12 January 2027
- Patient group submission deadline:
- TBC